COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Treatment of Meibomian Gland Dysfunction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01683318
Recruitment Status : Completed
First Posted : September 11, 2012
Last Update Posted : November 13, 2013
National University, Singapore
Information provided by (Responsible Party):
Louis Tong, Singapore National Eye Centre

Brief Summary:

The current study aims to test the efficacy of treatment for a device that utilises a thermal pulsation system, which applies heat from the inner surface of the eyelids (Lipiflow) in patients suffering from meibomian gland dysfunction.

Patients will be asked to undergo a one-time treatment with Lipiflow and the investigators will monitor them for changes in tear film and lipid composition, as well as changes in the anatomy of meibomian glands for over a study period of 12 weeks. Additionally, dry eye symptoms will be documented in form of questionnaires.

The investigators hypothesize that the treatment will be effective in improving clinical signs and will relieve dry eye symptoms for the patient. If this method of managing Meibomian Gland Dysfunction (MGD) is found to be efficacious and safe, it will be made available to patients in Singapore.

Condition or disease Intervention/treatment Phase
Meibomian Gland Dysfunction (MGD) Procedure: Thermal Pulsation therapy Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Thermal Pulsation System for the Treatment of Meibomian Gland Dysfunction
Study Start Date : September 2012
Actual Primary Completion Date : October 2013

Arm Intervention/treatment
Experimental: Treatment
Patients will undergo Thermal Pulsation treatment of Meibomian Gland Dysfunction using the TearScience System (Lipiflow).
Procedure: Thermal Pulsation therapy

Primary Outcome Measures :
  1. ocular discomfort [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Tear Break Up Time (TBUT) [ Time Frame: 3 months ]
  2. Number of blocked meibomian glands [ Time Frame: 3 months ]
  3. Corneal fluorescein staining score [ Time Frame: 3 months ]
  4. To measure the production of tears [ Time Frame: 3 months ]
    Schirmer's test uses paper strips inserted into the lower eyelid (conjunctival sac)for 5 minutes to measure the production of tears. Both eyes are tested at the same time. The paper is then removed and the amount of moisture is measured.

  5. Tear evaporimetry [ Time Frame: 3 months ]
  6. Lipid layer thickness [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Eyelids must present with blocked meibomian gland openings (plugs), at least 1 visible MG plug in the 4 eyelids, or discernable change in consistency of meibum (increased in viscosity or opacity) when MG expressed in upper or lower eyelids.
  2. At least one out of 8 questions on dry eye symptoms is answered with often or all the time.
  3. Eyes should not show any other ocular surface pathology which required more treatment than eye lubricant and conventional eyelid hygiene.

Exclusion Criteria:

  1. Known history of thyroid disorders (diagnosed by physician).
  2. No ocular surgery within the previous 6 months and LASIK within the previous 1 year.
  3. Any intake of central nervous system and hormonal drugs within last 30 days and inability to withhold such drugs for at least 6 weeks.
  4. Active ocular infection or pterygium.
  5. Anticipated necessity to wear contact lens in the duration of the study.
  6. Living in the same household as another participant of the study.
  7. Any other specified reason as determined by clinical investigator, for example, the need to use any treatment or eyedrops not permitted by the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01683318

Layout table for location information
Singapore National Eye Centre
Singapore, Singapore, 168751
Sponsors and Collaborators
Singapore National Eye Centre
National University, Singapore
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Louis Tong, Clinician-Scientist, Singapore National Eye Centre Identifier: NCT01683318    
Other Study ID Numbers: R913/22/2012
First Posted: September 11, 2012    Key Record Dates
Last Update Posted: November 13, 2013
Last Verified: September 2012